DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Eli Lilly - 2 William Blair - 2 It's - 1 Gregory Renza - 1 Renza - 1 Oppenheimer - 1 Jeff Jones - 1 Piper Sandler - 1
Top related locs:
Mariana Bristol Branchburg , New Jersey Indiana Biopharma’s Indianapolis PNT2002 U.S
Top related orgs:
Novartis - 2 pharma - 1 RBC Capital Markets - 1 TRT - 1 Mariana Oncology - 1 Janus - 1 Janus Henderson Investors - 1 Bristol - 1

Search resuls for: "PNT2002"


2 mentions found


☆ This up-and-coming cancer treatment could be a $25 billion market opportunity — it's already a hotbed for M&A
  + stars: | 2024-05-23 | by ( Michelle Fox | ) www.cnbc.com   time to read: +7 min
RBC Capital Markets sees a $25 billion market opportunity for the space. The average analyst rating is hold, with 8% upside to the average analyst price target, according to FactSet. Eli Lilly has an average analyst rating of overweight and 8.3% upside to the average analyst price target, according to FactSet. Stock Chart Icon Stock chart icon AstraZeneca's one-year performanceAstraZeneca shares have an average analyst rating of overweight and nearly 6% upside to the average analyst price target, according to FactSet. Stock Chart Icon Stock chart icon Bristol-Myers Squibb's one-year performance
Persons: It's, Gregory Renza, Renza, Oppenheimer, Jeff Jones, Piper Sandler, Edward Tenthoff, Eli Lilly, Dan Lyons, Janus Henderson, Myers Squibb, William Blair, Matt Phipps, Jefferies, Andrew Tsai, They've, Janus Henderson's Lyons, Jones, Piper Sandler's Tenthoff, Myers Organizations: pharma, RBC Capital Markets, TRT, Novartis, Mariana Oncology, Janus, Janus Henderson Investors, Bristol, RayzeBio, Karuna Therapeutics, AstraZeneca, Fusion Pharmaceuticals, GlobalData's Pharma Intelligence, Pluvicto Locations: Mariana, Bristol
☆ Lilly eyes targeted cancer therapies with $1.4 billion Point Biopharma deal
  + stars: | 2023-10-03 | by ( Bhanvi Satija | Leroy | ) www.reuters.com   time to read: +2 min
(Reuters) -Eli Lilly and Co will buy Point Biopharma Global for $1.4 billion, the companies said on Tuesday, gaining access to experimental therapies that enable precise targeting of cancer. Lilly has offered $12.50 per Point Biopharma share held, representing a premium of about 87% to the stock’s last close. Shares of Indiana-based Point Biopharma soared 85%, while Lilly’s stock was down about 3%. Point Biopharma has licensed both its late-stage experimental therapies to Lantheus Holdings since 2022. A Lantheus spokesperson said the company’s commercial rights remain intact and its collaboration with Point Biopharma is progressing in line with expectations.
Persons: Eli Lilly, Mike Segar, Lilly, ”, William Blair, Andy Hsieh Organizations: Reuters, Company, REUTERS, Dice Therapeutics, Novartis, Lantheus Holdings Locations: Branchburg , New Jersey, Indiana, Biopharma’s Indianapolis, PNT2002, U.S
0 next >>
Total: 2